Duncan Williams Asset Management LLC increased its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 32.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,660 shares of the healthcare product maker’s stock after acquiring an additional 1,141 shares during the period. Duncan Williams Asset Management LLC’s holdings in Abbott Laboratories were worth $527,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Groupama Asset Managment lifted its holdings in shares of Abbott Laboratories by 22.2% in the 3rd quarter. Groupama Asset Managment now owns 228,448 shares of the healthcare product maker’s stock worth $26,000 after acquiring an additional 41,557 shares during the last quarter. Future Financial Wealth Managment LLC bought a new stake in Abbott Laboratories in the third quarter worth $31,000. Peterson Financial Group Inc. bought a new position in shares of Abbott Laboratories during the third quarter valued at about $32,000. Valued Wealth Advisors LLC increased its holdings in shares of Abbott Laboratories by 78.4% in the third quarter. Valued Wealth Advisors LLC now owns 289 shares of the healthcare product maker’s stock worth $33,000 after buying an additional 127 shares during the period. Finally, Highline Wealth Partners LLC purchased a new stake in Abbott Laboratories during the 3rd quarter valued at about $37,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.
Abbott Laboratories Stock Up 1.5 %
ABT opened at $125.12 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $125.67. The stock has a market capitalization of $217.01 billion, a price-to-earnings ratio of 16.36, a PEG ratio of 2.51 and a beta of 0.73. The firm has a 50 day moving average price of $115.26 and a 200-day moving average price of $113.31.
Abbott Laboratories Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be issued a $0.59 dividend. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.55. This represents a $2.36 dividend on an annualized basis and a yield of 1.89%. The ex-dividend date of this dividend is Wednesday, January 15th. Abbott Laboratories’s payout ratio is currently 30.85%.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on the company. Stifel Nicolaus lifted their price target on Abbott Laboratories from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Thursday. Barclays upped their price target on shares of Abbott Laboratories from $143.00 to $149.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. UBS Group raised their price target on shares of Abbott Laboratories from $146.00 to $148.00 and gave the stock a “buy” rating in a report on Thursday. Jefferies Financial Group increased their target price on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock a “hold” rating in a report on Thursday, October 17th. Finally, Raymond James reissued a “buy” rating and issued a $129.00 price target (up from $122.00) on shares of Abbott Laboratories in a research note on Monday, October 14th. Four research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $132.50.
Get Our Latest Stock Analysis on ABT
Abbott Laboratories Company Profile
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Further Reading
- Five stocks we like better than Abbott Laboratories
- Buy P&G Now, Before It Sets A New All-Time High
- Bloom Energy: Powering the Future With Decentralized Energy
- 3 Healthcare Dividend Stocks to Buy
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Manufacturing Stocks Investing
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.